Matthew H G Katz

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
  2. pmc Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
    Matthew H G Katz
    Department of Surgery, The University of California, Orange, CA, USA
    Ann Surg Oncol 17:1794-801. 2010
  3. doi request reprint Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg 248:1098-102. 2008
  4. doi request reprint Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer
    Amanda B Cooper
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    J Am Coll Surg 219:111-20. 2014
  5. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
  6. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
  7. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
  8. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
  9. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
  10. pmc A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma
    Christina L Roland
    Division of Surgery, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:2056-63. 2012

Detail Information

Publications62

  1. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  2. pmc Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
    Matthew H G Katz
    Department of Surgery, The University of California, Orange, CA, USA
    Ann Surg Oncol 17:1794-801. 2010
    ..We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patients enrolled on two recently reported clinical trials...
  3. doi request reprint Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg 248:1098-102. 2008
    ..To describe our approach to resection of pancreatic head cancers, which involve 1 or both of the first-order branches of the superior mesenteric vein (SMV)...
  4. doi request reprint Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer
    Amanda B Cooper
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    J Am Coll Surg 219:111-20. 2014
    ..We sought to describe the treatment patterns and outcomes of a series of elderly patients with pancreatic cancer who were treated with a multimodality strategy that liberally used neoadjuvant therapy...
  5. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
    ..By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy...
  6. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
    ..To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma...
  7. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
    ..We conducted a phase II trial to assess the survival duration and quality of life of patients who received adjuvant interferon-based chemoradiation for pancreatic adenocarcinoma after pancreaticoduodenectomy...
  8. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
    ..There is no optimal treatment schema for this distinct stage of disease, so the role of surgery is undefined...
  9. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
    ..Following potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield...
  10. pmc A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma
    Christina L Roland
    Division of Surgery, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:2056-63. 2012
    ..However, the use of the LNR to predict distant recurrence risk remains unknown. The purpose of this study was to determine if the LNR is associated with distant recurrence risk...
  11. pmc Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    HPB (Oxford) 14:506-13. 2012
    ..The relationships between extent of hepatectomy, postoperative VTE and bleeding events were evaluated using the National Surgical Quality Improvement Program (NSQIP) database...
  12. doi request reprint Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2197-203. 2013
    ..Few data exist to guide oncologic surveillance following curative treatment of pancreatic cancer. We sought to identify a rational, cost-effective postoperative surveillance strategy...
  13. doi request reprint Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors
    Maria Q B Petzel
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:4078-84. 2012
    ....
  14. doi request reprint Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5749-56. 2012
    ..In this study, the authors sought to determine the rate at which neoadjuvant therapy is associated with a reduction in the size or stage of borderline resectable tumors...
  15. doi request reprint Treatment of borderline resectable pancreatic cancer
    Amanda B Cooper
    MD Anderson Cancer Center, 1400 Pressler Dr, Houston, TX, USA
    Curr Treat Options Oncol 14:293-310. 2013
    ..Coordination among a multidisciplinary team of physicians is necessary to maximize these complex patients' short- and long-term oncologic outcomes...
  16. doi request reprint Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival
    Ching Wei D Tzeng
    Department of Surgery, University of Kentucky, Lexington, KY, USA
    J Gastrointest Surg 18:16-24; discussion 24-5. 2014
    ..NT sequencing is a practical treatment strategy, particularly for patients at high biological or perioperative risk...
  17. pmc Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Arch Surg 147:513-9. 2012
    ..To calculate conditional survival estimates for patients with pancreatic adenocarcinoma...
  18. doi request reprint Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms
    Jordan M Cloyd
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Surg Oncol . 2016
    ..Long term patient-reported symptoms and quality of life (QOL) are important outcome metrics following cancer operations, but have been poorly described in patients who have previously undergone pancreatectomy...
  19. ncbi request reprint Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience
    Jordan M Cloyd
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1484, Houston, TX, 77030, USA
    J Gastrointest Surg . 2016
    ..The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) prior to pancreatoduodenectomy (PD)...
  20. ncbi request reprint Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality
    Jason W Denbo
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA
    J Gastrointest Surg 20:1975-1985. 2016
    ..The impact of preoperative chemoradiation on postoperative morbidity and mortality of patients with pancreatic adenocarcinoma remains controversial...
  21. pmc The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy
    Christina L Roland
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 22:S1221-8. 2015
    ..The lymph node ratio (LNR) is a prognostic marker of oncologic outcomes after NT and resection. In this study, we evaluated the effectiveness of postoperative therapy following NT, stratified by LNR...
  22. pmc Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
    Ching Wei D Tzeng
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    HPB (Oxford) 16:430-8. 2014
    ..The purpose of this study was to determine the relationship between carbohydrate antigen (CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with neoadjuvant therapy (NT)...
  23. doi request reprint Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification
    Ching Wei D Tzeng
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
    J Gastrointest Surg 18:146-55; discussion 155-6. 2014
    ..This study was designed to analyze the incidence and risk factors for post-pancreaticoduodenectomy (PD) morbidity/mortality in a multi-institutional cohort of BR-C patients...
  24. pmc Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
    Ryan M Thomas
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:1696-704. 2012
    ..Resection of certain recurrent malignancies can prolong survival, but resection of recurrent pancreatic ductal adenocarcinoma is typically contraindicated because of poor outcomes...
  25. pmc Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:e11-8. 2012
    ..The technical approaches we have described here can be used as a basic foundation for operative safety and efficiency during these challenging operations...
  26. pmc Current status of adjuvant therapy for pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 15:1205-13. 2010
    ..Well-designed prospective trials are needed to define the optimal adjuvant or neoadjuvant therapy strategy for these patients...
  27. pmc Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:337-44. 2011
    ..Standardization of surgical and pathologic techniques is crucial to the interpretation of studies evaluating adjuvant therapies for pancreatic cancer (PC)...
  28. doi request reprint Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 207:106-20. 2008
  29. ncbi request reprint Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei David Tzeng
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:293. 2012
    ..We sought to analyze resection rates, reasons for no resection, and outcomes after neoadjuvant therapy (NT) of patients with both resectable anatomy and either "operable" or "borderline" biology/physiology...
  30. doi request reprint Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis
    Jason W Denbo
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA
    J Gastrointest Surg . 2017
    ..Subsequent analyses concluded that its routine use is cost-effective. We hypothesized that selective administration of the drug to patients at high risk for POPF would be more cost-effective...
  31. pmc Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer
    Hop S Tran Cao
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, FCT 17 6058, Houston, TX, 77230 1402, USA
    J Gastrointest Surg 18:269-78; discussion 278. 2014
    ..We assessed the ability of radiographic criteria to predict the need for superior mesenteric-portal vein (SMV-PV) resection and the presence of histologic vein invasion...
  32. ncbi request reprint Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas
    Claudius Conrad
    Department of Surgical Oncology, Section of Hepato Pancreato Biliary Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler, Unit 1484, Houston, TX, 77030, USA
    J Gastrointest Surg 20:1966-1974. 2016
    ..The impact of lymph node (LN) status and lymphadenectomy (LA) on survival in pancreatic neuroendocrine tumors (pNETs) remains controversial. We evaluated the impact of tumor extension and grade on nodal metastasis and survival...
  33. doi request reprint Spleen and splenic vessel preserving distal pancreatectomy for bifocal PNET in a young patient with MEN1
    Claudius Conrad
    Division of Surgery, Department of Surgical Oncology, Hepato Pancreato Biliary Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler, Unit 1484, Houston, TX, 77030, USA
    Surg Endosc 30:4619. 2016
    ..Laparoscopic spleen preserving distal pancreatectomy can be performed with removal (Warshaw's technique) or preservation of the splenic vessels, the later having a higher rate of successful splenic preservation...
  34. doi request reprint Laparoscopic Insulinoma Enucleation from the Retro-Pancreatic Neck: A Stepwise Approach
    Claudius Conrad
    Department of Surgical Oncology, Hepato Pancreato Biliary Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 23:2001. 2016
    ..Although a laparoscopic approach is ideal, it can be particularly challenging when the insulinoma is retropancreatic or adjacent to critical vascular structures [i.e., superior mesenteric vein-portal vein confluence (SMV-PV)]...
  35. pmc Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma
    Jordan M Cloyd
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 122:2671-9. 2016
    ..However, the optimal preoperative regimen has not been established...
  36. ncbi request reprint Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
    Ryan Michael Thomas
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:252. 2012
    ..We sought to identify factors that may be associated with prolonged survival following resection of recurrent PDAC...
  37. doi request reprint Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors
    Laura Prakash
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484, PO Box 301402, Houston, 77230 1402, TX, USA
    J Gastrointest Surg 19:2011-8. 2015
    ..Surgical thrombectomy is often used to manage tumor thrombi that develop in association with cancers of the liver or kidney. We have likewise used thrombectomy to extract portal venous tumor thrombi in selected cases of pNET...
  38. pmc Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors
    Christine S Landry
    Department of Surgical Oncology, Baylor University Medical Center, 3410 Worth Street, Suite 235, Dallas, TX 75246, USA
    World J Surg 37:1695-700. 2013
    ..We hypothesized that the extent of lymphadenectomy reported in a large administrative database would be associated with overall survival for jejunal and ileal neuroendocrine tumors...
  39. pmc Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    HPB (Oxford) 16:373-83. 2014
    ..The secondary hypothesis was that patients at high risk for post-discharge VTE could be identified, potentially facilitating the selective use of extended chemoprophylaxis...
  40. ncbi request reprint Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors
    Laura Prakash
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484, PO Box 301402, Houston, TX, 77230 1402, USA
    J Gastrointest Surg . 2016
    ..We sought to validate our hypothesis that preoperative FAS may facilitate resection of locoregionally advanced pNETs by reducing the anatomic extent of the primary tumor...
  41. pmc Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
    David R Fogelman
    M D Anderson Cancer Center, 1515 Holcombe Drive, Houston, TX, 77030, USA
    J Cachexia Sarcopenia Muscle 5:307-13. 2014
    ..IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown...
  42. doi request reprint Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery
    Brian Badgwell
    Department of Surgical Oncology, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    J Surg Oncol 108:182-6. 2013
    ..The purpose of this prospective study was to identify risk factors for adverse outcomes or increased resource utilization after abdominal cancer surgery in geriatric patients...
  43. doi request reprint Tumor-node-metastasis staging of pancreatic adenocarcinoma
    Matthew H G Katz
    Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:111-25. 2008
    ....
  44. pmc Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer
    Hop S Tran Cao
    Department of Surgery, University of California at San Diego, California, USA
    Mol Cancer Ther 9:2068-78. 2010
    ..Our results suggest the potential of this therapeutic paradigm against pancreatic cancer in the adjuvant and maintenance settings...
  45. doi request reprint Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater
    Jordan M Cloyd
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol . 2017
    ..Although preoperative therapy is increasingly administered to patients with pancreatic adenocarcinoma, the role of preoperative therapy for patients with adenocarcinoma of the ampulla of Vater is undefined...
  46. ncbi request reprint Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC)
    David R Fogelman
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:219. 2012
    ..Symptoms such as pain, nausea and anorexia may predict weight loss. Inflammatory cytokines are also associated with cachexia. We evaluated the ability of each to predict weight loss in newly diagnosed PC patients...
  47. doi request reprint Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of "TeleDischarge"
    Matthew H G Katz
    The Minimally Invasive New Technologies in Oncologic Surgery MINTOS Cooperative Group, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    J Surg Res 202:196-203. 2016
    ..Virtual clinical encounters (VCEs) can now be conducted using widely available videoconferencing technologies. However, whether these technologies may be used to monitor postoperative recovery is unknown...
  48. pmc Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival
    Sun Mi Lee
    Departments of Pathology Surgical Oncology Gastrointestinal Medical Oncology Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Am J Surg Pathol 40:1653-1660. 2016
    ..The proposed HTRG scheme is simple and easy to apply in practice by pathologists and might be used as a successful surrogate for longer DFS in patients with potentially resectable PDAC who completed neoadjuvant therapy and surgery...
  49. doi request reprint Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer
    Amanda B Cooper
    Department of Surgery, Penn State Hershey Medical Center, Hershey, PA, USA
    Ann Surg Oncol 22:2416-23. 2015
    ..Little is known about changes in body composition that may occur during neoadjuvant therapy for pancreatic cancer. This study was designed to characterize these changes and their potential relationships with therapeutic outcomes...
  50. doi request reprint Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy
    Lilian Schwarz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 22:3522-9. 2015
    ..The authors hypothesized that morbidity after pancreatectomy is therefore underreported. They sought to compare rates of adverse events calculated at multiple time points after pancreatectomy...
  51. pmc Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer
    Christina L Roland
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    Ann Surg Oncol 22:1168-75. 2015
    ..In this study, we sought to evaluate cancer-specific endpoints in patients undergoing a NAC versus a surgery-first (SF) approach with specific emphasis on lymph node metastases...
  52. doi request reprint Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
    Matthew H G Katz
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2787-95. 2013
    ..Shortcomings have included an absence of staging and treatment standards and pre-existing biases with regard to the use of neoadjuvant therapy and the role of vascular resection at pancreatectomy...
  53. doi request reprint Current diagnosis and management of unusual pancreatic tumors
    Melinda M Mortenson
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg 196:100-13. 2008
    ....
  54. pmc Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101
    Matthew H G Katz
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston
    JAMA Surg 151:e161137. 2016
    ..Existing studies are retrospective and confounded by heterogeneity in patients studied, therapeutic algorithms used, and outcomes reported...
  55. pmc Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C
    Laura A Lambert
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:2181-7. 2009
    ..This study analyzes the incidence and risk factors for developing neutropenia following MMC-HIPEC combined with CRS...
  56. ncbi request reprint Associated vascular injury in patients with bile duct injury during cholecystectomy
    Alex M Keleman
    University of California, Irvine Medical Center, Orange, California, USA
    Am Surg 77:1330-3. 2011
    ....
  57. pmc Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?
    Amanda B Cooper
    Department of Surgery, Penn State Hershey, Hershey, PA, USA
    J Gastrointest Surg 19:80-6; discussion 86-7. 2015
    ..The impact of neoadjuvant therapy on postpancreatectomy complications is inadequately described...
  58. doi request reprint Management of borderline resectable pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Semin Radiat Oncol 24:105-12. 2014
    ..The rationale for and results following treatment with neoadjuvant chemotherapy and chemoradiation and subsequent surgical resection of the primary tumor are described in detail and existing data are reviewed. ..
  59. doi request reprint Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy
    Richard N Berri
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4008, USA
    J Am Coll Surg 214:778-87. 2012
    ..We hypothesized that sequential measurement of currently available serum proteins will indicate fluid balance...
  60. ncbi request reprint Current concepts in multimodality therapy for retroperitoneal sarcoma
    Matthew H G Katz
    The University of Texas, MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:159-68. 2007
    ....
  61. doi request reprint Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy
    David Roife
    Department of General Surgery, The University of Texas Health Science Center at Houston, Houston, TX
    Surgery . 2017
    ..We hypothesized that xenograft tumors could be grown from smaller volumes of patient tissue, such as those obtained during diagnostic biopsies...
  62. ncbi request reprint Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis
    Matthew H G Katz
    Department of Surgery, University of California San Diego, San Diego, California 92103, USA
    Hepatogastroenterology 51:842-6. 2004
    ..This study investigates histopathologic factors that contribute to the superior outcome of these patients...